Ara-290vsTB-500 + BPC-157 + GHK-Cu

Ara-290 is an 11-amino-acid peptide designed to selectively activate the innate repair receptor (IRR), a heteromeric receptor complex composed of the erythropoietin receptor (EPOR) and the beta common receptor (CD131/βcR). This receptor is distinct from the classical homodimeric EPOR that mediates erythropoiesis, which is why Ara-290 can deliver tissue-protective effects without stimulating red blood cell production or the thrombotic risks associated with EPO.

The IRR is expressed on tissues subjected to metabolic stress, inflammation, or injury — including neurons, Schwann cells, cardiomyocytes, renal tubular cells, and endothelial cells. When Ara-290 activates the IRR, it triggers a cascade of protective signaling pathways: JAK2/STAT5 activation promotes anti-apoptotic gene expression (Bcl-2, Bcl-xL); PI3K/Akt signaling provides cell survival signals; NF-κB modulation shifts the inflammatory balance from pro-inflammatory to pro-resolution. The net effect is protection of viable cells from death, reduction of inflammation, and activation of repair processes.

Ara-290's most clinically advanced application is in peripheral neuropathy, particularly diabetic small fiber neuropathy. Schwann cells — the myelinating glial cells of the peripheral nervous system — express the IRR, and Ara-290 stimulates their survival and regenerative capacity. In clinical trials, subcutaneous Ara-290 administration improved corneal nerve fiber density (a measure of small fiber regeneration) and reduced neuropathic symptoms. Despite its extremely short plasma half-life (approximately 2 minutes), the tissue-protective effects persist for days because the cellular signaling cascades activated by IRR engagement have sustained downstream effects that outlast the peptide's presence in circulation.

This triple combination adds the copper peptide GHK-Cu to the BPC-157/TB-500 healing stack, introducing a third distinct mechanism — copper-dependent enzymatic tissue remodeling — alongside the NO/growth factor signaling of BPC-157 and the actin-mediated cell migration of TB-500.

GHK-Cu contributes uniquely through its ability to deliver bioavailable copper to cells and activate copper-dependent enzymes. Lysyl oxidase, a copper-dependent enzyme, catalyzes the cross-linking of collagen and elastin fibers, which is essential for creating organized, structurally sound connective tissue rather than disorganized scar tissue. Superoxide dismutase (SOD), another copper-dependent enzyme, provides antioxidant defense at the wound site, protecting newly forming tissue from oxidative damage. GHK-Cu also stimulates the synthesis of collagen types I and III, elastin, glycosaminoglycans, and decorin — the fundamental building blocks of the extracellular matrix.

The theoretical three-layer synergy works as follows: TB-500 acts first by mobilizing repair cells through actin regulation and reducing acute inflammation. BPC-157 creates the vascular and biochemical infrastructure for repair through angiogenesis and growth factor upregulation. GHK-Cu then supports the remodeling phase — the final stage of wound healing where disorganized early repair tissue is replaced with properly structured, functional tissue. GHK-Cu's gene-regulatory effects (modulating expression of over 4,000 genes) may also amplify the effects of the other two peptides by creating a favorable transcriptional environment for regeneration. As with the dual BPC/TB stack, no clinical data exists for this specific triple combination.